文献速递眼底病与葡萄膜炎

羟氯喹视网膜病变相关的脉络膜变薄

Choroidal Thinning Associated With Hydroxychloroquine Retinopathy.
PubMed 文献 · Am J Ophthalmol · 2017-09-08

回顾性病例系列纳入124例接受羟氯喹治疗的系统性红斑狼疮或类风湿关节炎患者,按有无羟氯喹视网膜病变分组,用扫频源OCT测量脉络膜厚度。结果显示视网膜病变组脉络膜厚度显著降低,尤其毛细血管层等效厚度,且与累积剂量/体重相关。

要点

  • 羟氯喹视网膜病变组脉络膜厚度较对照组显著降低(P < .05),但黄斑颞侧1.5 mm处除外。
  • 毛细血管层等效厚度在所有测量位置组间均有显著差异。
  • 累积剂量/体重与中心凹下脉络膜及毛细血管层等效厚度显著相关(均P = .001)。

核心结论

  • 结果提示羟氯喹视网膜病变与脉络膜变薄相关,尤其累及毛细血管层。
  • 作者认为结果可能提示羟氯喹毒性存在脉络膜受累。

研究设计与样本

  • 回顾性病例系列,机构设置。
  • 纳入124例接受羟氯喹治疗的系统性红斑狼疮或类风湿关节炎患者,按有无羟氯喹视网膜病变分为视网膜病变组和对照组。

主要发现

  • 羟氯喹视网膜病变组脉络膜厚度较对照组显著降低(P < .05),但黄斑颞侧1.5 mm处除外。
  • 毛细血管层等效厚度在所有脉络膜位置组间均有显著差异。
  • 中到大血管层厚度仅在少数位置有显著差异。
  • 累积剂量/体重与中心凹下脉络膜厚度及毛细血管层等效厚度显著相关(均P = .001)。
  • 校正年龄、羟氯喹使用诊断、屈光不正和羟氯喹使用时长后,羟氯喹视网膜病变与中心凹下脉络膜厚度(P = .001)及毛细血管层等效厚度(P = .003)的关联仍有统计学意义。

关键数值与推荐

  • 使用扫频源OCT(SS-OCT;DRI-OCT,Topcon Inc,东京,日本)由2名独立研究者手动测量总脉络膜厚度和毛细血管层等效厚度。
  • 测量位置为中心凹及距中心凹鼻侧和颞侧0.5、1.5、3 mm处。
  • 中到大血管层厚度据此计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate choroidal thickness in patients using hydroxychloroquine (HCQ) and compare choroidal thickness between eyes with and without HCQ retinopathy. DESIGN: Retrospective case series. METHODS: Setting: Institutional. PATIENTS: We included 124 patients with systemic lupus erythematosus or rheumatoid arthritis who were treated with HCQ. The patients were divided into an HCQ retinopathy group and a control group, according to the presence or absence of HCQ retinopathy. OBSERVATION: Total choroidal thickness and choriocapillaris-equivalent thickness were measured manually by 2 independent investigators using swept-source optical coherence tomography (SS-OCT; DRI-OCT, Topcon Inc, Tokyo, Japan). These measurements were made at the fovea and at nasal and temporal locations 0.5, 1.5, and 3 mm from the fovea. Medium-to-large vessel layer thickness was calculated accordingly. The thicknesses were compared between the HCQ retinopathy and control groups. We performed correlation analyses between choroidal thicknesses and details regarding HCQ use. MAIN OUTCOME MEASURES: Total choroidal thickness and choriocapillaris-equivalent thickness. RESULTS: Choroidal thicknesses were significantly decreased (P < .05) in the HCQ retinopathy group compared to the control group, except at the temporal choroid 1.5 mm from the fovea. Choriocapillaris-equivalent thicknesses were significantly different in all choroidal locations between the groups. In contrast, the medium-to-large vessel layer thickness was only significantly different at a few locations. The cumulative dose/body weight was significantly correlated with subfoveal choroidal and choriocapillaris-equivalent thicknesses (both P = .001). The association between presence of HCQ retinopathy and choroidal thicknesses was also statistically significant after adjusting for age, diagnosis for HCQ use, refractive errors, and duration of HCQ use (P = .001 and P = .003 for subfoveal choroidal and choriocapillaris-equivalent thickness, respectively). CONCLUSIONS: These results all suggest that HCQ retinopathy is associated with choroidal thinning, especially in the choriocapillaris. Our results may suggest choroidal involvement of HCQ toxicity.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ahn SJ, Ryu SJ, Joung JY, et al. Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. Am J Ophthalmol. 2017. PMID: 28890078. doi:10.1016/j.ajo.2017.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。